-
What is your approach when it comes to treatment of partners of patients with sexually transmitted diseases (STDs)? A new research analysis indicates that patient-delivered partner therapy (PDPT) and home sampling for partners can be effective management strategies to reduce STD occurrence in partners of patients with an existing infection.
-
Working to eliminate syphilis in your patient population? Use the practical materials available in the Syphilis Elimination Effort (SEE) toolkit developed by the Centers for Disease Control and Prevention (CDC).
-
What is your clinic doing to boost syphilis testing? An innovative social marketing campaign, "Healthy Penis," has been associated with an increase in syphilis tests in gay and bisexual men in San Francisco.
-
Women who are interested in nonhormonal contraception will see wider access to the Today contraceptive sponge now that a new company is in charge of its marketing and distribution.
-
The next patient in your examination room is an adolescent female who says she wants the "acne pill." What are your options?
-
Students who seek contraceptive services at college and university health centers are facing sticker shock when it comes to picking up their supplies. As a result of changes to the federal Deficit Reduction Act (DRA) that were implemented in January 2007, institutions of higher education no longer qualify for special reduced pricing for contraceptive supplies.
-
AHC Media appreciates the faith you have placed in us to provide you with practical, authoritative information.
-
As clinicians begin to integrate use of the first cervical cancer vaccine (Gardasil, Merck & Co., Whitehouse Station, NJ) into their practice, developers of an investigational vaccine have launched a head-to-head study of the two vaccines.
-
The National Association of Nurse Practitioners in Women's Health (NPWH) has announced its endorsement of cervical cancer screening guidelines that support the use of HPV (human papillomavirus) testing along with the Pap test for routine screening of women 30 and older.
-
While two advanced trials have been closed for one microbicide candidate for HIV prevention in women, researchers are pressing forward in examining other contenders that may prove safe and effective in the fight against the AIDS epidemic.